{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:31:43Z","timestamp":1782826303395,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Research Supporting Program of the Korean Association for the Study of the Liver","award":["KASL2020-01"],"award-info":[{"award-number":["KASL2020-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12072-022-10310-1","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T01:02:22Z","timestamp":1648083742000},"page":"294-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV\u2013DNA level\u2009&lt;\u20092000\u00a0IU\/mL"],"prefix":"10.1007","volume":"16","author":[{"given":"Hankil","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-2496","authenticated-orcid":false,"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"2","key":"10310_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol"},{"issue":"4","key":"10310_CR2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology"},{"issue":"4","key":"10310_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","volume":"26","author":"HJ Yim","year":"2020","unstructured":"Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol 2020;26(4):411\u2013429. https:\/\/doi.org\/10.3350\/cmh.2020.0049","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10310_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10(1):1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4","journal-title":"Hepatol Int"},{"issue":"2","key":"10310_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jhep.2018.02.032","volume":"69","author":"YC Hsu","year":"2018","unstructured":"Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol 2018;69(2):278\u2013285. https:\/\/doi.org\/10.1016\/j.jhep.2018.02.032","journal-title":"J Hepatol"},{"issue":"1","key":"10310_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-017-0966-6","volume":"15","author":"A Berzigotti","year":"2017","unstructured":"Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med 2017;15(1):200. https:\/\/doi.org\/10.1186\/s12916-017-0966-6","journal-title":"BMC Med"},{"issue":"4","key":"10310_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3350\/cmh.2020.0016","volume":"26","author":"J Kim","year":"2020","unstructured":"Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, et al. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26(4):516\u2013528. https:\/\/doi.org\/10.3350\/cmh.2020.0016","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10310_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3350\/cmh.2020.0022","volume":"26","author":"CRA Lesmana","year":"2020","unstructured":"Lesmana CRA, Raharjo M, Gani RA. Managing liver cirrhotic complications: overview of esophageal and gastric varices. Clin Mol Hepatol 2020;26(4):444\u2013460. https:\/\/doi.org\/10.3350\/cmh.2020.0022","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10310_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3350\/cmh.2019.0010n","volume":"26","author":"Korean Association for the Study of the Liver (KASL)","year":"2020","unstructured":"Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26(2):83\u2013127. https:\/\/doi.org\/10.3350\/cmh.2019.0010n.","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"10310_CR10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/apt.12721","volume":"39","author":"G D'Amico","year":"2014","unstructured":"D\u2019Amico G, Pasta L, Morabito A, D\u2019Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39(10):1180\u20131193. https:\/\/doi.org\/10.1111\/apt.12721","journal-title":"Aliment Pharmacol Ther"},{"key":"10310_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.14309\/ajg.0000000000001497","volume":"117","author":"HW Lee","year":"2022","unstructured":"Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, et al. Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus-DNA< 2,000 IU\/mL. Am J Gastroenterol. 2022;117:288\u2013294.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10310_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/hep.27889","volume":"62","author":"DH Sinn","year":"2015","unstructured":"Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015;62(3):694\u2013701. https:\/\/doi.org\/10.1002\/hep.27889","journal-title":"Hepatology"},{"key":"10310_CR13","unstructured":"http:\/\/opendata.hira.or.kr\/op\/opc\/olap3thDsInfo.do#none. Accessed 22 Dec 2021"},{"issue":"4","key":"10310_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics 2016;34(4):349\u2013361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10310_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3904\/kjim.2016.096","volume":"32","author":"JY Cho","year":"2017","unstructured":"Cho JY, Sohn W, Sinn DH, Gwak GY, Paik YH, Choi MS, et al. Long-term real-world entecavir therapy in treatment-na\u00efve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med 2017;32(4):636\u2013646. https:\/\/doi.org\/10.3904\/kjim.2016.096","journal-title":"Korean J Intern Med"},{"issue":"7","key":"10310_CR16","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s10620-019-05489-7","volume":"64","author":"JH Kwon","year":"2019","unstructured":"Kwon JH, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK, et al. Efficacy and safety of tenofovir disoproxil fumarate in treatment-na\u00efve patients with chronic hepatitis B in Korea. Dig Dis Sci 2019;64(7):2039\u20132048. https:\/\/doi.org\/10.1007\/s10620-019-05489-7","journal-title":"Dig Dis Sci"},{"key":"10310_CR17","unstructured":"Ahn DG, Lee JI, Lee KS, Kim S, Kim SU, Kim BK, et al. Two-year treatment with tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with chronic hepatitis B. Proc Liver Week 2020;190"},{"key":"10310_CR18","unstructured":"https:\/\/opendata.hira.or.kr\/op\/opc\/selectPatDataAplInfoView.do. Accessed 10 July 2019"},{"issue":"3","key":"10310_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","volume":"71","author":"SU Kim","year":"2019","unstructured":"Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea. J Hepatol 2019;71(3):456\u2013464. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.028","journal-title":"J Hepatol"},{"issue":"12","key":"10310_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jvh.12971","volume":"25","author":"BG Kim","year":"2018","unstructured":"Kim BG, Park NH, Lee SB, Lee H, Lee BU, Park JH, et al. Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat 2018;25(12):1565\u20131575. https:\/\/doi.org\/10.1111\/jvh.12971","journal-title":"J Viral Hepat"},{"issue":"12","key":"10310_CR21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.cgh.2018.04.063","volume":"16","author":"JW Jang","year":"2018","unstructured":"Jang JW, Choi JY, Kim YS, Yoo JJ, Woo HY, Choi SK, et al. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2018;16(12):1954-1963.e1953. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.063","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10310_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223678","volume":"14","author":"BK Kim","year":"2019","unstructured":"Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS ONE 2019;14(10): e0223678. https:\/\/doi.org\/10.1371\/journal.pone.0223678","journal-title":"PLoS ONE"},{"key":"10310_CR23","unstructured":"https:\/\/www.ubcare.co.kr\/Contents\/26\/. Accessed 20 Dec 2021"},{"issue":"1","key":"10310_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hep.31267","volume":"73","author":"S Dave","year":"2021","unstructured":"Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, et al. Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatology 2021;73(1):68\u201378. https:\/\/doi.org\/10.1002\/hep.31267","journal-title":"Hepatology"},{"issue":"2","key":"10310_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","volume":"19","author":"WM Choi","year":"2021","unstructured":"Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19(2):246-258.e249. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10310_CR26","doi-asserted-by":"publisher","first-page":"e00299","DOI":"10.14309\/ctg.0000000000000299","volume":"12","author":"H Lee","year":"2021","unstructured":"Lee H, Kim BK, Jang S, Ahn SH. Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic hepatitis B to prevent liver disease progression. Clin Transl Gastroenterol 2021;12(2):e00299. https:\/\/doi.org\/10.14309\/ctg.0000000000000299","journal-title":"Clin Transl Gastroenterol"},{"key":"10310_CR27","unstructured":"Center for Korean Network for Organ Sharing. Annual Report of the Transplant 2019. https:\/\/www.konos.go.kr\/konosis\/common\/bizlogic.jsp. Accessed 20 May 2021"},{"key":"10310_CR28","unstructured":"Health Insurance Review and Assessment Service, Guidelines for economic evaluation of pharmaceuticals in Korea, March 2021. http:\/\/www.hira.or.kr\/sViewer\/index.do?ebookSn=630. Accessed 6 June 2021"},{"key":"10310_CR29","unstructured":"Health Insurance Review and Assessment Service, drug reimbursement list in Korea, March 2021. https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014050000&brdScnBltNo=4&brdBltNo=1640. Accessed 6 June 2021"},{"key":"10310_CR30","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"L Kim","year":"2014","unstructured":"Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36: e2014008. https:\/\/doi.org\/10.4178\/epih\/e2014008","journal-title":"Epidemiol Health"},{"issue":"4","key":"10310_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/hep.30330","volume":"69","author":"HL Kim","year":"2019","unstructured":"Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 2019;69(4):1599\u20131613. https:\/\/doi.org\/10.1002\/hep.30330","journal-title":"Hepatology"},{"issue":"3","key":"10310_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057900","volume":"8","author":"JY Park","year":"2013","unstructured":"Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim YS, et al. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS ONE 2013;8(3): e57900. https:\/\/doi.org\/10.1371\/journal.pone.0057900","journal-title":"PLoS ONE"},{"issue":"2","key":"10310_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.11005\/jbm.2016.23.2.63","volume":"23","author":"JW Kwon","year":"2016","unstructured":"Kwon JW, Park HY, Kim YJ, Moon SH, Kang HY. Cost-effectiveness of pharmaceutical interventions to prevent osteoporotic fractures in postmenopausal women with osteopenia. J Bone Metab 2016;23(2):63\u201377. https:\/\/doi.org\/10.11005\/jbm.2016.23.2.63","journal-title":"J Bone Metab."},{"issue":"1","key":"10310_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nep.13203","volume":"24","author":"DS Go","year":"2019","unstructured":"Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton) 2019;24(1):56\u201364. https:\/\/doi.org\/10.1111\/nep.13203","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10310_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008;11(3):527\u2013538","journal-title":"Value Health"},{"issue":"11","key":"10310_CR36","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/lt.22388","volume":"17","author":"F \u00c5berg","year":"2011","unstructured":"\u00c5berg F, M\u00e4klin S, R\u00e4s\u00e4nen P, Roine RP, Sintonen H, Koivusalo AM, et al. Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score. Liver Transpl 2011;17(11):1333\u20131343","journal-title":"Liver Transpl"},{"key":"10310_CR37","unstructured":"Korea National Health and Nutrition Examination Survey, 2019. https:\/\/knhanes.kdca.go.kr\/knhanes\/eng\/index.do. Accessed 9 May 2021"},{"issue":"6","key":"10310_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 2012;15(6):835\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2012.04.014","journal-title":"Value Health"},{"key":"10310_CR39","unstructured":"https:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2019\/02\/weodata\/weorept.aspx?pr.x=45&pr.y=21&sy=2016&ey=2021&scsm=1&ssd=1&sort=country&ds=.&br=1&c=542&s=NGDP_RPCH%2CNGDPD%2CPPPGDP%2CNGDPDPC%2CPPPPC%2CPCPIPCH&grp=0&a=. Accessed 6 June 2021"},{"issue":"5","key":"10310_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jvh.12832","volume":"25","author":"YC Hsu","year":"2018","unstructured":"Hsu YC, Ho HJ, Lee TY, Huang YT, Wu MS, Lin JT, et al. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat 2018;25(5):543\u2013551. https:\/\/doi.org\/10.1111\/jvh.12832","journal-title":"J Viral Hepat"},{"issue":"7","key":"10310_CR41","first-page":"1","volume":"11","author":"CB Chun","year":"2009","unstructured":"Chun CB, Kim SY, Lee JY, Lee SY. Republic of Korea: health system review. Health Syst Transit 2009;11(7):1\u2013184","journal-title":"Health Syst Transit"},{"key":"10310_CR42","unstructured":"https:\/\/repository.hira.or.kr\/handle\/2019.oak\/2541. Accessed 11 Dec 2021"},{"issue":"9","key":"10310_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvh.13306","volume":"27","author":"JY Cho","year":"2020","unstructured":"Cho JY, Sohn W, Paik YH, Gwak GY, Choi MS, Lee JH, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients-Functional cure unlikely. J Viral Hepat 2020;27(9):951\u2013954. https:\/\/doi.org\/10.1111\/jvh.13306","journal-title":"J Viral Hepat"},{"issue":"4","key":"10310_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","volume":"59","author":"WK Seto","year":"2013","unstructured":"Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013;59(4):709\u2013716. https:\/\/doi.org\/10.1016\/j.jhep.2013.06.007","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10310-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10310-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10310-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T10:05:28Z","timestamp":1650189928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10310-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10310"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10310-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"4 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare for Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board. The need for patient consent was waived due to the use of untraceable and de-identified secondary claims data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research (ethics)"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate (ethics)"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish (ethics)"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Plant reproducibility"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials registration"}}]}}